Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model

P. L. Gehlbach, R. L. Purple, P. E. Hallaway, B. E. Hedlund

Research output: Contribution to journalArticle

Abstract

Purpose. The iron chelating agent deferoxamine mesylate USP (Desferal, Ciba, Summit, NJ) is commonly used in the treatment of acute iron intoxication and chronic iron overload (associated with the transfusion- dependent anemias). When used for prolonged periods of time or in high doses deferoxamine is attended by a range of ocular toxicities. The visual symptoms associated with deferoxamine administration often limit effective iron chelation therapy and can result in permanent vision loss. Deferoxamine has recently been conjugated to certain high molecular weight biocompatible polymers without altering its iron-binding properties. Here the effect of conjugation of deferoxamine to hydroxyethyl starch on retinal toxicity is examined. Methods. An albino rat model of electroretinographically determined, deferoxamine-induced retinal toxicity has been previously described. We use this model to evaluate and compare both native deferoxamine and hydroxyethyl starch conjugated deferoxamine. Results. Our data show that retinal function, as assessed by the electroretinogram b-wave, is significantly depressed 1 day after a single dose of native deferoxamine, while the b-waves of rats receiving a single dose of hydroxyethyl starch- deferoxamine, are not significantly depressed at any time during the study. In addition, the administered dose of hydroxyethyl starch-deferoxamine resulted in plasma deferoxamine concentrations up to live times greater than those achieved with native deferoxamine. Conclusion. These results suggest that hydroxyethyl starch conjugated deferoxamine is associated with less retinal toxicity than native deferoxamine and that it may be a safer alternative for iron chelation therapy.

Original languageEnglish (US)
Pages (from-to)2871-2877
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume34
Issue number10
StatePublished - 1993
Externally publishedYes

Fingerprint

Deferoxamine
Polymers
Starch
Iron
Chelation Therapy
Iron Chelating Agents
Iron Overload

Keywords

  • albino rats
  • deferoxamine
  • ERG
  • retinopathy
  • toxicity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. / Gehlbach, P. L.; Purple, R. L.; Hallaway, P. E.; Hedlund, B. E.

In: Investigative Ophthalmology and Visual Science, Vol. 34, No. 10, 1993, p. 2871-2877.

Research output: Contribution to journalArticle

Gehlbach, P. L. ; Purple, R. L. ; Hallaway, P. E. ; Hedlund, B. E. / Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. In: Investigative Ophthalmology and Visual Science. 1993 ; Vol. 34, No. 10. pp. 2871-2877.
@article{73ff3bf06122465f8d4746397f848b0f,
title = "Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model",
abstract = "Purpose. The iron chelating agent deferoxamine mesylate USP (Desferal, Ciba, Summit, NJ) is commonly used in the treatment of acute iron intoxication and chronic iron overload (associated with the transfusion- dependent anemias). When used for prolonged periods of time or in high doses deferoxamine is attended by a range of ocular toxicities. The visual symptoms associated with deferoxamine administration often limit effective iron chelation therapy and can result in permanent vision loss. Deferoxamine has recently been conjugated to certain high molecular weight biocompatible polymers without altering its iron-binding properties. Here the effect of conjugation of deferoxamine to hydroxyethyl starch on retinal toxicity is examined. Methods. An albino rat model of electroretinographically determined, deferoxamine-induced retinal toxicity has been previously described. We use this model to evaluate and compare both native deferoxamine and hydroxyethyl starch conjugated deferoxamine. Results. Our data show that retinal function, as assessed by the electroretinogram b-wave, is significantly depressed 1 day after a single dose of native deferoxamine, while the b-waves of rats receiving a single dose of hydroxyethyl starch- deferoxamine, are not significantly depressed at any time during the study. In addition, the administered dose of hydroxyethyl starch-deferoxamine resulted in plasma deferoxamine concentrations up to live times greater than those achieved with native deferoxamine. Conclusion. These results suggest that hydroxyethyl starch conjugated deferoxamine is associated with less retinal toxicity than native deferoxamine and that it may be a safer alternative for iron chelation therapy.",
keywords = "albino rats, deferoxamine, ERG, retinopathy, toxicity",
author = "Gehlbach, {P. L.} and Purple, {R. L.} and Hallaway, {P. E.} and Hedlund, {B. E.}",
year = "1993",
language = "English (US)",
volume = "34",
pages = "2871--2877",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "10",

}

TY - JOUR

T1 - Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model

AU - Gehlbach, P. L.

AU - Purple, R. L.

AU - Hallaway, P. E.

AU - Hedlund, B. E.

PY - 1993

Y1 - 1993

N2 - Purpose. The iron chelating agent deferoxamine mesylate USP (Desferal, Ciba, Summit, NJ) is commonly used in the treatment of acute iron intoxication and chronic iron overload (associated with the transfusion- dependent anemias). When used for prolonged periods of time or in high doses deferoxamine is attended by a range of ocular toxicities. The visual symptoms associated with deferoxamine administration often limit effective iron chelation therapy and can result in permanent vision loss. Deferoxamine has recently been conjugated to certain high molecular weight biocompatible polymers without altering its iron-binding properties. Here the effect of conjugation of deferoxamine to hydroxyethyl starch on retinal toxicity is examined. Methods. An albino rat model of electroretinographically determined, deferoxamine-induced retinal toxicity has been previously described. We use this model to evaluate and compare both native deferoxamine and hydroxyethyl starch conjugated deferoxamine. Results. Our data show that retinal function, as assessed by the electroretinogram b-wave, is significantly depressed 1 day after a single dose of native deferoxamine, while the b-waves of rats receiving a single dose of hydroxyethyl starch- deferoxamine, are not significantly depressed at any time during the study. In addition, the administered dose of hydroxyethyl starch-deferoxamine resulted in plasma deferoxamine concentrations up to live times greater than those achieved with native deferoxamine. Conclusion. These results suggest that hydroxyethyl starch conjugated deferoxamine is associated with less retinal toxicity than native deferoxamine and that it may be a safer alternative for iron chelation therapy.

AB - Purpose. The iron chelating agent deferoxamine mesylate USP (Desferal, Ciba, Summit, NJ) is commonly used in the treatment of acute iron intoxication and chronic iron overload (associated with the transfusion- dependent anemias). When used for prolonged periods of time or in high doses deferoxamine is attended by a range of ocular toxicities. The visual symptoms associated with deferoxamine administration often limit effective iron chelation therapy and can result in permanent vision loss. Deferoxamine has recently been conjugated to certain high molecular weight biocompatible polymers without altering its iron-binding properties. Here the effect of conjugation of deferoxamine to hydroxyethyl starch on retinal toxicity is examined. Methods. An albino rat model of electroretinographically determined, deferoxamine-induced retinal toxicity has been previously described. We use this model to evaluate and compare both native deferoxamine and hydroxyethyl starch conjugated deferoxamine. Results. Our data show that retinal function, as assessed by the electroretinogram b-wave, is significantly depressed 1 day after a single dose of native deferoxamine, while the b-waves of rats receiving a single dose of hydroxyethyl starch- deferoxamine, are not significantly depressed at any time during the study. In addition, the administered dose of hydroxyethyl starch-deferoxamine resulted in plasma deferoxamine concentrations up to live times greater than those achieved with native deferoxamine. Conclusion. These results suggest that hydroxyethyl starch conjugated deferoxamine is associated with less retinal toxicity than native deferoxamine and that it may be a safer alternative for iron chelation therapy.

KW - albino rats

KW - deferoxamine

KW - ERG

KW - retinopathy

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=0027165843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027165843&partnerID=8YFLogxK

M3 - Article

C2 - 7689545

AN - SCOPUS:0027165843

VL - 34

SP - 2871

EP - 2877

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 10

ER -